We investigated differences in immune restoration and onset of new AIDS-defining events on combination antiretroviral therapy (cART) among HIV type-1 (HIV-1)-infected patients of different regional origin now living in the Netherlands.
Methods
Treatment-naive adults reaching plasma viral load (pVL)<400 copies/ml within 9 months of starting cART were selected from the Netherlands ATHENA cohort. CD4+ T-cell response on cART was determined over 7 years using mixed models. CD4+ T-cell counts were excluded from the analyses at the first of two consecutive measurements of pVL≥400 copies/ml following prior suppression to <400 copies/ml. Multivariate analyses included gender, age, CD4+ T-cell count and pVL prior to cART, hepatitis coinfection, HIV-1 transmission and region of origin (Western Europe/North America [WN], sub- Saharan Africa [SSA], Southeast Asia [SEA], Latin America/Caribbean [LAC] or other).
Results
For 6,057 selected patients (WN 3,947, SSA 989, SEA 237, LAC 695 and other 189), median follow-up was 3.2 years (WN 3.3, SSA 2.9, SEA 3.2, LAC 2.7 and other 2.7). CD4+ T-cell increase in the first 6 months of cART was lower in males than females (-26 cells/mm3; P<0.0001) and in patients from SSA compared with WN (-36 cells/mm3; P<0.0001). Because men from SSA started with lower CD4+ T-cell counts than men from WN, they continued to lag behind and had lower absolute CD4+ T-cell counts after 7 years of cART. Furthermore, cumulative tuberculosis incidence after 7 years of cART was higher in SSA compared with WN (4.5% versus 0.5%, hazard ratio 5.08, 95% confidence interval 2.22–11.60).
Conclusions
HIV-1-infected immigrants from SSA have blunted immune restoration on fully suppressive cART and should be identified at an earlier disease stage. Our results call for more intensive screening for both latent and active tuberculosis in these patients.
References
1.
The Data Collection on Adverse Events of Anti-HIV Drugs.(D:A:D) Study Group. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies.AIDS2008; 22: 2143–2153.
2.
MocroftA., LedergerberB., KatlamaC.Decline in the AIDS and death rates in the EuroSIDA study: an observational study.Lancet2003; 362: 22–29.
3.
LewdenC., RaffiF., CheneG., SobelA., LeportC.Mortality in a cohort of HIV-infected adults started on a protease inhibitor-containing therapy: standardization to the general population.J Acquir Immune Defic Syndr2001; 26: 480–482.
4.
JaggyC., von OverbeckJ., LedergerberB.Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population.Lancet2003; 362: 877–878.
5.
KeiserO., TaffeP., ZwahlenM.All cause mortality in the Swiss HIV Cohort Study from 1990 to 2001 in comparison with the Swiss population.AIDS2004; 18: 1835–1843.
6.
Jensen-FangelS., PedersenL., PedersenC.Low mortality in HIV-infected patients starting highly active antiretroviral therapy: a comparison with the general population.AIDS2004; 18: 89–97.
7.
Antiretroviral Therapy Cohort Collaboration.Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies.Lancet2008; 372: 293–299.
8.
LewdenC., CheneG., MorlatP.HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population.J Acquir Immune Defic Syndr2007; 46: 72–77.
9.
GrasL., van SighemA., SmitC.Monitoring of human immunodeficiency virus (HIV) infection in the Netherlands. Amsterdam: HIV Monitoring Foundation2008.
10.
GrasL., KesselringA.M., GriffinJ.T.CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater.J Acquir Immune Defic Syndr2007; 45: 183–192.
11.
NellenJ.F., WitF.W., de WolfF., JurriaansS., LangeJ.M., PrinsJ.M.Virologic and immunologic response to highly active antiretroviral therapy in indigenous and nonindigenous HIV-1-infected patients in the Netherlands.J Acquir Immune Defic Syndr2004; 36: 943–950.
12.
FraterA.J., DunnD.T., BeardallA.J.Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy.AIDS2002; 16: 1139–1146.
13.
MocroftA., PhillipsA.N., GatellJ.Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study.Lancet2007; 370: 407–413.
14.
MooreR.D., KerulyJ.C.CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.Clin Infect Dis2007; 44: 441–446.
15.
GarciaF., de LazzariE., PlanaM.Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count.J Acquir Immune Defic Syndr2004; 36: 702–713.
16.
KaufmannG.R., PerrinL., PantaleoG.CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.Arch Intern Med2003; 163: 2187–2195.
17.
NashD., KatyalM., BrinkhofM.W.Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies.AIDS2008; 22: 2291–2302.
18.
JonesJ.L., HansonD.L., DworkinM.S., DeCockK.M.HIV-associated tuberculosis in the era of highly active antiretroviral therapy. The Adult/Adolescent Spectrum of HIV Disease Group.Int J Tuberc Lung Dis2000; 4: 1026–1031.
19.
Santoro-LopesG., de PinhoA.M., HarrisonL.H., SchechterM.Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy.Clin Infect Dis2002; 34: 543–546.
20.
BadriM., WilsonD., WoodR.Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study.Lancet2002; 359: 2059–2064.
21.
LawnS.D., BadriM., WoodR.Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort.AIDS2005; 19: 2109–2116.
22.
The Antiretroviral Therapy Cohort Collaboration.Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America.Clin Infect Dis2005; 41: 1772–1782.
23.
LawnS.D., BekkerL.G., WoodR.How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control.AIDS2005; 19: 1113–1124.
24.
PatelN.R., SwanK., LiX., TachadoS.D., KozielH.Impaired M. tuberculosis-mediated apoptosis in alveolar macrophages from HIV+ persons: potential role of IL-10 and BCL-3.J Leukoc Biol2009; 86: 53–60.
25.
ElziL., SchlegelM., WeberR.Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission.Clin Infect Dis2007; 44: 94–102.
26.
World Health Organization. A guide to monitoring and evaluation for collaborative TB/HIV activities. Geneva: World Health Organization2009.
27.
KitahataM.M., GangeS.J., AbrahamA.G.Effect of early versus deferred antiretroviral therapy for HIV on survival.N Engl J Med2009; 360: 1815–1826.
28.
When To Start Consortium.Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.Lancet2009; 373: 1352–1363.
BonnetF., ThiebautR., CheneG.Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996–2002.HIV Med2005; 6: 198–205.
31.
EggerM., MayM., CheneG.Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.Lancet2002; 360: 119–129.
32.
SmitC., HallettT.B., LangeJ., GarnettG., de WolfF.Late entry to HIV care limits the impact of anti-retroviral therapy in the Netherlands.PLoS One2008; 3: e1949.
33.
KalinkovichA., WeismanZ., BursteinR., BentwichZ.Standard values of T-lymphocyte subsets in Africa.J Acquir Immune Defic Syndr Hum Retrovirol1998; 17: 183–185.
34.
KassaE., Rinke de WitT.F., HailuE.Evaluation of the World Health Organization staging system for HIV infection and disease in Ethiopia: association between clinical stages and laboratory markers.AIDS1999; 13: 381–389.
UrassaW., BakariM., SandstromE.Rate of decline of absolute number and percentage of CD4 T lymphocytes among HIV-1-infected adults in Dar es Salaam, Tanzania.AIDS2004; 18: 433–438.
37.
MesseleT., AbdulkadirM., FontanetA.L.Reduced naive and increased activated CD4 and CD8 cells in healthy adult Ethiopians compared with their Dutch counterparts.Clin Exp Immunol1999; 115: 443–450.
38.
MekonnenY., GeskusR.B., HendriksJ.C.Low CD4 T cell counts before HIV-1 seroconversion do not affect disease progression in Ethiopian factory workers.J Infect Dis2005; 192: 739–748.
39.
MüllerV., von WylV., YerlyS.African descent is associated with slower CD4 cell count decline in treatment-naive patients of the Swiss HIV Cohort Study.AIDS2009; 23: 1269–1276.
40.
KankiP.J., HamelD.J., SankaleJ.L.Human immunodeficiency virus type 1 subtypes differ in disease progression.J Infect Dis1999; 179: 68–73.
41.
VasanA., RenjifoB., HertzmarkE.Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype.Clin Infect Dis2006; 42: 843–852.
42.
KiwanukaN., LaeyendeckerO., RobbM.Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection.J Infect Dis2008; 197: 707–713.
43.
FellayJ., ShiannaK.V., GeD.A whole-genome association study of major determinants for host control of HIV-1.Science2007; 317: 944–947.
44.
JoyR., DruytsE.F., BrandsonE.K.Impact of neighborhood-level socioeconomic status on HIV disease progression in a universal health care setting.J Acquir Immune Defic Syndr2008; 47: 500–505.
